InTouch and ASCO Announce New Cancer Information Feature
InTouch magazine, the Good Health Guide to Cancer Prevention and Treatment, has joined forces with the American Society of Clinical Oncology (ASCO).
InTouch magazine, the Good Health Guide toCancer Prevention and Treatment, has joined forces with the American Society ofClinical Oncology (ASCO). Beginning with the May 2002 issue of InTouch, ASCOwill contribute a regular page to the magazine, which is published six times ayear.
"InTouch is committed to providing cancer patients andtheir families with comprehensive information on cancer prevention and treatmentoptions," said Randi Londer Gould, managing editor of InTouch."Teaming with ASCO adds strength to our efforts and broadens the scope ofthe resources we provide for our readers."
The new feature combines the oncologist-approved cancerinformation contained in InTouch with the latest news from ASCO. The debutcolumn will highlight ASCO’s patient information materials and onlineresources, including their new cancer information website, People Living WithCancer, scheduled to launch in May.
"ASCO is all about taking care of patients," saidLarry Norton, MD, ASCO President. "ASCO serves the people who treat peoplewith cancer. This collaboration with InTouch, which shares our commitment toenhancing patient-physician communication, will enable ASCO to reach even morepatients with the information they need to make informed decisions about theirhealth care."
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
